Best-in-RAS

Redefining what’s possible in precision oncology to treat RAS-dependent cancers

Taking Precision Oncology to New Heights

We are a clinical-stage company unraveling the complex role of RAS in cancer to drive drug discovery & development

Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.

We uncover novel approaches targeting the RAS signaling pathway so that we can translate findings into clinical applications near term.

With a trusted team of world-leading RAS cancer biologists, expert medicinal chemists, and proven drug developers, our collaborative ecosystem creates novel RAS-targeted small molecules to maximize patient benefit.

Inhibiting Active RAS

Going beyond current approaches,
we aim to inhibit the active “ON” state.

Decades of scientific research demonstrating the crucial role of RAS signaling in cancer has culminated in the opportunity to translate our knowledge into real-world solutions for patients.

We use our expert understanding of RAS signaling biology to inform rational drug design, yielding multiple approaches, including the selective inhibition of RAS-driven PI3K activation and a broad spectrum of KRAS mutants in both the “ON” and “OFF” states.

Rationally Designed to Maximize Patient Benefit

We’re overcoming the limitations of current RAS-targeted approaches, aiming to realize the full promise of KRAS and PI3K inhibition.

Program & Indication

Pre-Clinical Phase 1 Phase 2 Phase 3

BBO-8520

- Phase 1

A direct inhibitor targeting the “ON” and “OFF” states of KRAS. We are currently enrolling the ONKORAS-101 trial for patients with KRAS^G12C mutant non-small cell lung cancer (NSCLC).

ONKORAS-101 is an open-label, multi-center Phase 1a/1b study designed to evaluate the safety, tolerability, preliminary antitumor activity, and pharmacokinetics of BBO-8520 as a single agent and in combination with pembrolizumab in patients with KRAS^G12C mutant NSCLC.

BBO-10203

- Pre-Clinical

A PI3Kα:RAS breaker designed to inhibit PI3Kα/AKT signaling in tumors while critically avoiding hyperglycemia. We anticipate patient enrollment later in the year.

BBO-11818

- Pre-Clinical

A pan-KRAS inhibitor targeting its “ON” and “OFF” states with high potency against both G12D and G12V mutants. We expect to file an IND in early 2025.